MERIT MEDICAL SYSTEMS INC — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 45/100
What the filing says
Merit Medical reported Q2 2026 revenue of $418.8M (up 10% YoY; 9% organic constant currency), with GAAP EPS of $0.65 (up 20%) and non-GAAP EPS of $1.19 (up 18%). The company raised full-year 2026 revenue guidance to $1.631–$1.643B (from $1.612–$1.634B) and non-GAAP EPS guidance to $4.25–$4.35 (from $4.01–$4.15), reflecting better-than-expected H1 performance. Management also completed three acquisitions (View Point, C2, Biolife) and one divestiture (DualCap for $28M to Health Line in February 2026).
Why this rating
Guidance raise and organic growth acceleration are real but modest relative to company size (~$5.4B market cap). ~0.8% revenue uplift to guidance is routine. No transformational event.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.